ApolloMed Q1 revenue $337M (+28% YoY), EPS $0.31 flat; appoints Chan Basho CFO

Astrana Health, Inc.

2023-Q1 EPS reported $0.31 revenue$337,244,000

Q1 revenue $337.2M (+28% YoY), net income attributable $14.6M (+3%), diluted EPS $0.31 (flat YoY).
Adjusted EBITDA $29.8M vs $34.4M, decrease driven by higher investments and non-cash gains.
Chan Basho appointed permanent CFO (was interim); will remain Chief Strategy Officer.
Acquired For Your Benefit (FYB) and received CA DMHC approval for Knox-Keene health plan, enabling global risk assumption.
Reaffirms FY23 guidance: revenue $1.3B-$1.5B, net income $49.5M-$71.5M, adj EBITDA $120M-$160M, EPS $0.95-$1.20.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Chan Basho

Chief Financial Officer

ASTH · Astrana Health, Inc.

Effective: 2023-05-05
Filed: May 8, 2023, 7:59 PM ET

On May 5, 2023, the Company’s Board of Directors appointed Chan Basho as Chief Financial Officer and principal financial officer.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Astrana Health, Inc. reported first quarter ended March 31, 2023 results: revenue $337.2 million, net income $14.6 million, EPS $0.31. Guidance reaffirmed.

Period: first quarter ended March 31, 2023
Revenue: $337.2 million
Net income: $14.6 million
EPS: $0.31
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Apollo Medical Holdings, Inc. (“ApolloMed,” and together with its subsidiaries and affiliated entities, the “Company”) (NASDAQ: AMEH), a leading physician-centric, technology-powered healthcare company focused on enabling providers in the successful delivery of value-based care, today announced its consolidated financial results for the first quarter ended March 31, 2023. Financial Highlights for First Quarter Ended March 31, 2023: • Total revenue of $337.2 million, up 28% from $263.3 million for the prior-year quarter • Net income attributable to ApolloMed of $14.6 million, up 3% from $14.3 million for the prior-year quarter • Earnings per share - diluted (“EPS - diluted”) of $0.31, compared to $0.31 per share for the prior-year quarter

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Chan Basho was appointed as Chief Financial Officer at Astrana Health, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On May 5, 2023, the Company’s Board of Directors appointed Chan Basho as Chief Financial Officer and principal financial officer.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Astrana Health, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-016464

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.